ArticleFrontiers in endocrinology2026
Mortality trends in diabetes with proxy-defined steatotic liver disease in the United States, 1999-2023.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To characterize U.S. mortality trends for diabetes mellitus (DM), proxy-defined metabolic dysfunction-associated steatotic liver disease (MASLD), and deaths listing both conditions, and to present exploratory conditional overlap extrapolations through 2040. Methods: We analyzed CDC WONDER multiple-cause-of-death data from 1999-2023 among adults aged ≥25 years. DM was identified by ICD-10 codes E10-E14 and steatotic liver disease by K75.8 or K76.0. Because clinical MASLD cannot be directly ascertained in CDC WONDER, MASLD was defined using a death-certificate proxy combining steatotic liver disease codes with recorded cardiometabolic conditions. Age-adjusted mortality rates were assessed using Joinpoint regression. Prophet models generated conditional extrapolations through 2040. Sensitivity analyses used K76.0-only coding, K75.8-only coding, restriction to 1999-2019, and an underlying-cause-of-death-only analysis requiring K76.0 to be listed as the underlying cause of death. Results: DM-involved mortality changed little from 1999 to 2023 (118.47 to 122.61 per 100,000; average annual percent change [AAPC], -0.03%). In contrast, overlap mortality increased from 0.08 to 0.84 per 100,000 (AAPC, 11.20%), and proxy-defined MASLD mortality increased from 0.13 to 1.29 per 100,000 (AAPC, 9.83%), although absolute rates remained low. Sensitivity analyses using K76.0-only coding, restriction to 1999-2019, and an underlying-cause-of-death-only definition showed directionally consistent increases, whereas K75.8-only overlap deaths were sparse, zero, or suppressed. The underlying-cause-only analysis also showed a directionally consistent increase from 2000 to 2023 (AAPC, 14.46%; 95% CI, 13.46 to 21.51). Conditional extrapolations suggested continued growth through 2040 but were inherently uncertain. Conclusions: Proxy-based mortality involving co-recorded DM and steatotic liver disease increased substantially in U.S. death-certificate data. These findings were directionally consistent across alternative coding, period-restricted, and underlying-cause-only sensitivity analyses but remain limited by under-ascertainment, misclassification, and evolving death-certificate documentation. They should be interpreted as descriptive surveillance patterns rather than evidence of biological expansion or causal mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.